Elevated epithelial ATG16L1 expression in KRAS mutant MSS-CRC tumors strongly associated with decreased overall survival in response to atezolizumab (anti-PD-L1) alone or in combination with the MEK inhibitor cobimetinib. Here, ATG16L1 is linked to colorectal carcinoma.